Neurogene Inc. (NGNE)
NASDAQ: NGNE
· Real-Time Price · USD
19.61
-0.26 (-1.31%)
At close: Sep 04, 2025, 3:59 PM
19.30
-1.58%
After-hours: Sep 04, 2025, 07:00 PM EDT
-1.31% (1D)
| Bid | 13.94 |
| Market Cap | 279.87M |
| Revenue (ttm) | -925K |
| Net Income (ttm) | -84.39M |
| EPS (ttm) | -4.31 |
| PE Ratio (ttm) | -4.55 |
| Forward PE | -3.57 |
| Analyst | Buy |
| Ask | 24.81 |
| Volume | 56,712 |
| Avg. Volume (20D) | 158,612 |
| Open | 19.91 |
| Previous Close | 19.87 |
| Day's Range | 19.30 - 19.91 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.58 |
About NGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+28.36%
Neurogene shares are trading higher after the comp...
Unlock content with
Pro Subscription
3 months ago
-7.12%
Neurogene shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $38 to $24.
4 weeks ago · businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
